These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 14614664)

  • 1. Response to lamivudine treatment in children with chronic hepatitis B virus infection.
    Hagmann S; Chung M; Rochford G; Jani M; Trinh-Shevrin C; Sitnitskaya Y; Neumann AU; Pollack H
    Clin Infect Dis; 2003 Dec; 37(11):1434-40. PubMed ID: 14614664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
    Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
    Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon.
    Hartman C; Berkowitz D; Shouval D; Eshach-Adiv O; Hino B; Rimon N; Satinger I; Kra-Oz T; Daudi N; Shamir R
    Pediatr Infect Dis J; 2003 Mar; 22(3):224-9. PubMed ID: 12634582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial.
    Chan HL; Wang H; Niu J; Chim AM; Sung JJ
    Antivir Ther; 2007; 12(3):345-53. PubMed ID: 17591024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
    Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Med Virol; 2005 Apr; 75(4):491-8. PubMed ID: 15714490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
    Shin JW; Chung YH; Choi MH; Kim JA; Ryu SH; Jang MK; Kim IS; Park NH; Lee HC; Lee YS; Suh DJ
    J Gastroenterol Hepatol; 2005 Jun; 20(6):844-9. PubMed ID: 15946130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Kao JH; Chen DS
    Liver Int; 2008 Aug; 28(7):1034-41. PubMed ID: 18492018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
    Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
    Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
    Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
    Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of lamivudine-induced HBsAg loss rate according to age in children with chronic hepatitis B].
    Kim JM; Choe BH; Chu MA; Cho SM
    Korean J Hepatol; 2009 Jun; 15(2):168-78. PubMed ID: 19581769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Chen DS; Kao JH
    Antivir Ther; 2009; 14(2):203-10. PubMed ID: 19430095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy.
    Chen CH; Lee CM; Lu SN; Changchien CS; Wang JC; Wang JH; Hung CH; Hu TH
    J Hepatol; 2006 Jan; 44(1):76-82. PubMed ID: 16298013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of HBV-DNA fluctuations on virus-specific CD8+ T cells in HBeAg+ chronic hepatitis B patients treated with a steroid and lamivudine.
    Gotto J; Webster GJ; Brown D; Jenkins J; Dusheiko GM; Bertoletti A
    J Viral Hepat; 2006 Jun; 13(6):415-25. PubMed ID: 16842445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients.
    Wang CC; Liu CJ; Lai MY; Kao JH; Chen DS
    Liver Int; 2007 Mar; 27(2):235-9. PubMed ID: 17311619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
    Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
    J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B.
    Chan HL; Wong VW; Hui AY; Tsang SW; Chan JL; Chan HY; Wong GL; Sung JJ
    Antivir Ther; 2006; 11(4):465-71. PubMed ID: 16856620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
    Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
    Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
    Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
    J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with response to lamivudine: Retrospective study in a tertiary care clinic serving patients with chronic hepatitis B.
    Hann HW; Jonsson Funk ML; Rosenberg DM; Davis R
    J Gastroenterol Hepatol; 2005 Mar; 20(3):433-40. PubMed ID: 15740489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C.
    Kobayashi M; Suzuki F; Akuta N; Suzuki Y; Arase Y; Ikeda K; Hosaka T; Sezaki H; Kobayashi M; Iwasaki S; Sato J; Watahiki S; Miyakawa Y; Kumada H
    J Med Virol; 2006 Oct; 78(10):1276-83. PubMed ID: 16927289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.